Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
A phase 1/2 trial of [212Pb]Pb-MP0712 in neuroendocrine tumours, small-cell lung cancer, pancreatic ductal adenocarcinoma and bladder & urothelial cancer, run by Molecular Partners AG, now recruiting.
Overview
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors is a phase 1/2 interventional study registered as NCT07278479 by Molecular Partners AG, with 138 participants planned, started 2026-05-18 and due to reach its primary completion in 2028-09. Interventions recorded: [212Pb]Pb-MP0712.
Similar pages
not linked directly; found by shared links- TrialStudy of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Shares Bladder & urothelial cancer, Small-cell lung cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialStudy of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
Shares Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
- TrialDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.
- TrialStudy of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
Shares Molecular Partners and the tag pipeline.
- TrialCarcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
Shares Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialTargeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Shares Neuroendocrine tumours, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialStudy of Oral MRT-2359 in Selected Cancer Patients
Shares Neuroendocrine tumours, Small-cell lung cancer and the tag pipeline.